Effect of Rose-colored Glass on Mood

Mood Clinical Trial

Official title:

Effect of Rose-colored Glass on Mood: A Randomized Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03992586
• Other study ID #: RCG101
• Status: Completed
• Phase: N/A
• Start date: August 30, 2018
• Est. completion date: June 30, 2019

Study information

• Verified date: August 2020
• Source: Florida Center for Dermatology
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Decades of psychological research has highlighted the impact of visual perception on mood and happiness. The investigators hypothesized that literally seeing the world through rose colored glasses may have an effect on perception, mood, and happiness. After cataract surgery, which classically increases the vividness of perceived colors, patients report significant satisfaction. The investigators therefore sought to explore whether using pink colored lenses leads to a measurable impact on outcomes.

Description:

A randomized controlled clinical trial design will be performed. Subjects will be randomized for either pink lenses (treatment group) or clear lenses (placebo group).

Subjects will be asked to wear the assigned glasses throughout the day during the course of the trial. Glasses will not be work while driving at night.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 38
• Est. completion date: June 30, 2019
• Est. primary completion date: June 30, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects over 18 years of age.

Exclusion Criteria:

• Subjects who wear glasses on a regular basis.

Related Conditions & MeSH terms

• Mood

Intervention

Other:
• Wearing pink glasses
Wearing pink-colored lenses
• Wearing clear glasses
Wearing clear glasses

Locations

Country	Name	City	State
United States	St Vincent's Medical Center	Jacksonville	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Florida Center for Dermatology

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in Anxiety Scores on the Visual Analogue Scale at 1 week	Scale range 0-100, higher values represent more anxiety	1 week
Secondary	Change from baseline in Mood Scores on the Visual Analogue Scale	Scale range 0-100, higher values represent more sadness	1 week
Secondary	Change from baseline in Happiness Scores on the Visual Analogue Scale	Scale range 0-100, higher values represent more happiness	1 week
Secondary	Change from baseline in the Center for Epidemiological Studies Depression Scale score	Scale range 0-60, higher values suggest more depressive symptoms	1 week